Literature DB >> 8632915

Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus.

P Shaw1, J Freeman, R Bovey, R Iggo.   

Abstract

The carboxy-terminus of p53 contains a basic region which represses DNA binding, and this repression can be relieved by PAb421, an antibody against the basic region. The EB-1 human cell line contains wild type p53 protein which fails to express the PAb421 epitope and is highly active both in biological assays and in DNA binding assays. We show by wheat germ agglutinin chromatography and galactosyl-transferase labelling that this p53 is O-glycosylated, and that at least one of the sugar residues masks the PAb421 epitope, as demonstrated by recovery of reactivity with PAb421 after digestion of Western blots of EB-1 cell extract with hexosaminidase. A minor population of p53 molecules in EB-1 cells lacks the modification, and there is a correlation between the ability to bind DNA with high affinity and masking of the PAb421 epitope. We also show that strongly positively charged peptides, including short peptides from the basic region of p53, can derepress DNA binding, probably by disruption of an intramolecular interaction involving the basic region. We propose that any intervention which prevents this intramolecular interaction, including addition of bulky residues such as sugar groups, can activate DNA binding by p53.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632915

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage.

Authors:  K Webley; J A Bond; C J Jones; J P Blaydes; A Craig; T Hupp; D Wynford-Thomas
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  In vitro evolution of thermostable p53 variants.

Authors:  I Matsumura; A D Ellington
Journal:  Protein Sci       Date:  1999-04       Impact factor: 6.725

3.  Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding.

Authors:  F Janus; N Albrechtsen; U Knippschild; L Wiesmüller; F Grosse; W Deppert
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

4.  Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.

Authors:  S Nakamura; J A Roth; T Mukhopadhyay
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

5.  Protein O-GlcNAcylation: A critical regulator of the cellular response to stress.

Authors:  John C Chatham; Richard B Marchase
Journal:  Curr Signal Transduct Ther       Date:  2010-01

6.  Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53.

Authors:  Y Wu; H Huang; Z Miner; M Kulesz-Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 7.  Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system.

Authors:  Norbert Fülöp; Richard B Marchase; John C Chatham
Journal:  Cardiovasc Res       Date:  2006-07-29       Impact factor: 10.787

8.  Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53.

Authors:  A L Okorokov; F Ponchel; J Milner
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

9.  The Role of the O-GlcNAc Modification in Regulating Eukaryotic Gene Expression.

Authors:  Sandii Brimble; Edith E Wollaston-Hayden; Chin Fen Teo; Andrew C Morris; Lance Wells
Journal:  Curr Signal Transduct Ther       Date:  2010

Review 10.  The role of protein O-linked beta-N-acetylglucosamine in mediating cardiac stress responses.

Authors:  John C Chatham; Richard B Marchase
Journal:  Biochim Biophys Acta       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.